Allogeneic marrow transplantation in patients with severe systemic sclerosis: Resolution of dermal fibrosis

Arthritis and Rheumatism

Volumn 54, Issue 6, 2006, Pages 1982-1986

  Nash, Richard A ^a,b,g   McSweeney, Peter A ^c   Nelson, J Lee ^a,b   Wener, Mark ^b   Georges, George E ^a,b   Langston, Amelia A ^d   Shulman, Howard ^a,b   Sullivan, Keith M ^e   Lee, Julie ^a   Henstorf, Gretchen ^a   Storb, Rainer ^a,b   Furst, Daniel E ^f  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c Rocky Mountain Cancer Center   (United States)

^d EMORY UNIVERSITY   (United States)

^e DUKE UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE; THYMOCYTE ANTIBODY;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; DISEASE SEVERITY; EFFECTOR CELL; EXPERIMENTAL MODEL; FEMALE; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; MYELOABLATIVE CONDITIONING; OPPORTUNISTIC INFECTION; PATIENT SAFETY; PRIORITY JOURNAL; SKIN BIOPSY; SYSTEMIC SCLEROSIS;

ADULT; BONE MARROW TRANSPLANTATION; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORINE; FEMALE; FIBROSIS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; MYELOABLATIVE AGONISTS; SCLERODERMA, SYSTEMIC; SKIN; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 33745040938     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21908     Document Type: Article

References (17)

1. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
2. Storb R, Blume KG, O'Donnell MR, Chauncey T, Forman SJ, Deeg HJ, et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biol Blood Marrow Transplant 2001;7:39-44.
3. Radich JP, Gooley T, Bensinger W, Chauncey T, Clift R, Flowers M, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003;102:31-5.
4. Walters MC, Patience M, Leisenring W, Eckman JR, Scott JP, Mentzer WC, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996;335:369-76.
5. Sodani P, Gaziev D, Polchi P, Erer B, Giardini C, Angelucci E, et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood 2004;104:1201-3.
6. Good RA, Ikehara S. Preclinical investigations that subserve efforts to employ bone marrow transplantation for rheumatoid or autoimmune diseases. J Rheumatol Suppl 1997;48:5-12.
7. Van Bekkum DW. Stem cell transplantation in experimental models of autoimmune disease [review]. J Clin Immunol 2000;20:10-6.
8. Nash RA. Allogeneic HSCT for autoimmune diseases: conventional conditioning regimens. Bone Marrow Transplant 2003;32 Suppl 1:877-80.
9. McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, Dansey R, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002;100:1602-10.
10. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
11. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26:1346-53.
12. Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-versus-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988;72:546-54.
13. Anderson JE, Sale G, Appelbaum FR, Chauncey TR, Storb R. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol 1997;98:1010-6.
14. Farge D, Passweg J, van Laar JM, Marjanovic Z, Besenthal C, Finke J, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 2004;63:974-81.
15. Hymes SR, Simonton SC, Farmer ER, Beschorner WB, Tutschka PJ, Santos GW. Cutaneous busulfan effect in patients receiving bone-marrow transplantation. J Cutan Pathol 1985;12:125-9.
16. Khorshid O, Hosing C, Bibawi S, Ueno N, Reveille J, Mayes MD, et al. Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus. J Rheumatol 2004;31:2513-6.
17. Griffith LM, Pavletic SZ, Tyndall A, Bredeson CN, Bowen JD, Childs RW, et al. Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant 2005;11:862-70.